Anti-CD30 Antibodies that Bind to Intact CD30 but not to Soluble CD30
Description of Invention:
Human CD30 is a promising target for cancer immunotherapy since CD30 is highly expressed in Hodgkin’s disease and anaplastic large-cell lymphoma. However, soluble CD30, the extracellular domain of CD30 that is shed from the cells, can reduce the effects of CD30-targeting agents by competitive binding.
This invention is the first successful attempt of producing CD30-targeting agents without the disadvantage of the reducing effects caused by soluble CD30. More specifically, two (2) epitopes on membrane-associated CD30 have been identified that are missing on soluble CD30. These epitopes are potentially superior targets for immunotherapy since targeting the epitopes should be free from the competitive effects of soluble CD30. Accordingly, the antibodies described in this invention may be used as targeting reagents for cancer therapy.
Inventors:
Satoshi Nagata and Ira Pastan (NCI)
Patent Status:
DHHS Reference No. E-208-2005/0 --
U.S. Provisional Application No. 60/681,929 filed 16 May 2005
PCT Application No. PCT/US2006/019128 filed 16 May 2006, which published as WO 2007/040653 on 12 Apr 2007
Licensing Status: In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.
Portfolios: Cancer
Cancer -Therapeutics-Immunoconjugates Cancer -Diagnostics Cancer -Therapeutics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
